白血球表面抗原CD47治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0369
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:156
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Leukocyte Surface Antigen CD47 – Pipeline Review, H2 2019
Summary

According to the recently published report ‘Leukocyte Surface Antigen CD47 – Pipeline Review, H2 2019′; Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 53 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes.

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells.

The report ‘Leukocyte Surface Antigen CD47 – Pipeline Review, H2 2019′ outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 1, 28 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Diffuse Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Glioblastoma Multiforme (GBM), Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Marginal Zone B-cell Lymphoma, Melanoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Cerebral (Fatal) Malaria, Chronic Lymphocytic Leukemia (CLL), Colon Carcinoma, Diabetic Retinopathy, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tract Cancer, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Leiomyosarcoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Myeloproliferative Disorders, Neuroendocrine Tumors, Non-Small Cell Lung Carcinoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Peripheral T-Cell Lymphomas (PTCL), Sezary Syndrome, Thymic Carcinoma and Transitional Cell Cancer (Urothelial Cell Cancer).

Scope

- The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
- The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – Overview
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – Companies Involved in Therapeutics Development
Abpro Corp
ALX Oncology Inc
Arch Oncology Inc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biocad
Bristol-Myers Squibb Co
EpicentRx Inc
Forty Seven Inc
GeneScience Pharmaceuticals Co Ltd
GigaGen Inc
Hummingbird Bioscience Pte Ltd
I-Mab Biopharma Co Ltd
ImmuneOncia Therapeutics LLC
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
KAHR medical Ltd
LynkCell Inc
MesaGen LLC
NovImmune SA
Opsyon
Paradigm Shift Therapeutics LLC
Phanes Therapeutics Inc
PharmAbcine Inc
Shanghai Henlius Biotech Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
TOT Biopharm Co Ltd
Trillium Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – Drug Profiles
ABP-160 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-148 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abpro Corp, H2 2019
Pipeline by ALX Oncology Inc, H2 2019
Pipeline by Arch Oncology Inc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
Pipeline by Biocad, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by EpicentRx Inc, H2 2019
Pipeline by Forty Seven Inc, H2 2019
Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by ImmuneOncia Therapeutics LLC, H2 2019
Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, H2 2019
Pipeline by Innovent Biologics Inc, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by KAHR medical Ltd, H2 2019
Pipeline by LynkCell Inc, H2 2019
Pipeline by MesaGen LLC, H2 2019
Pipeline by NovImmune SA, H2 2019
Pipeline by Opsyon, H2 2019
Pipeline by Paradigm Shift Therapeutics LLC, H2 2019
Pipeline by Phanes Therapeutics Inc, H2 2019
Pipeline by PharmAbcine Inc, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Sorrento Therapeutics Inc, H2 2019
Pipeline by Surface Oncology Inc, H2 2019
Pipeline by Synthon Holdings BV, H2 2019
Pipeline by TOT Biopharm Co Ltd, H2 2019
Pipeline by Trillium Therapeutics Inc, H2 2019
Pipeline by Waterstone Hanxbio Pty Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Abpro Corp
ALX Oncology Inc
Arch Oncology Inc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biocad
Bristol-Myers Squibb Co
EpicentRx Inc
Forty Seven Inc
GeneScience Pharmaceuticals Co Ltd
GigaGen Inc
Hummingbird Bioscience Pte Ltd
I-Mab Biopharma Co Ltd
ImmuneOncia Therapeutics LLC
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
KAHR medical Ltd
LynkCell Inc
MesaGen LLC
NovImmune SA
Opsyon
Paradigm Shift Therapeutics LLC
Phanes Therapeutics Inc
PharmAbcine Inc
Shanghai Henlius Biotech Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
TOT Biopharm Co Ltd
Trillium Therapeutics Inc
Waterstone Hanxbio Pty Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[白血球表面抗原CD47治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆